Currently, the treatment sessions have concluded: thirty sessions, sixty Greys, marked by many mornings spent sitting quietly beneath the machine’s cold hum. Throughout it all, she showed up undeterred, fearless, driven by a quiet confidence that this time she’d overcome it and wouldn’t need surgery again. 

She now says she’s doing well, and in many ways she is. However, her body shows the toll of every treatment and recovery. Her oral health has worsened: teeth loosening, gums fragile, ulcers from medications and radiation. Her voice, which was slurred after her second operation, has regained strength: soft but clear, coherent, steady. She speaks less now, but each word is deliberate. 

The scar tissue around her neck has softened, fading into a pale crescent that no longer alarms her when she looks in the mirror. During the first weeks of radiation, it looked like a second-degree burn, raw, angry, painful. She feared her hair would fall out too, but it didn’t. Small mercies matter in battles like this. 

By the twelfth or thirteenth session, doctors observed her remarkable tolerance; they sensed her spirit was unbreakable, as if she had quietly decided that the disease could take her strength but not her dignity. 

Now, she undergoes regular check-ups. During each, they gently palpate her throat, searching for swelling or other irregularities that might indicate recurrence. She remains calm, watching their faces, interpreting their silences more than their words.

The year nears its end again, another December. Her only wish now is to get through this month without a concerning scan, a hospital stay, or another “we need to talk.” She no longer asks for years just more time to breathe, enjoy morning light, and live free from the fears pressing on her heart. 

Her legacy, in many ways, transcends her illness. Reflecting on her two-year journey with leiomyosarcoma of the thyroid, what stands out is her silent dignity. In a world where rare cancers often remain in the shadows of medical literature, she became my first mentor in perseverance, patience, and the importance of asking questions when answers are absent. 

She endured everything: surgeries, radiation, blood tests, hormone therapy, fear, and scars healing more slowly than time. Yet, her greatest fear wasn’t death; it was being forgotten in the incomplete pages of research—like countless others whose names never cross the margins of medical journals. 

Watching her face each recurrence revealed the systemic cracks: delayed referrals, limited diagnostics, poor coordination—that can determine whether a disease is caught early or progresses irreversibly. Her story was more than personal; it was scientific. Every unanswered “why” after her diagnosis became a research question, a pathway to explore, a gene to understand. 

She used to say, “I just want to get through one more December without it coming back.” That simple, human wish became my purpose. I don’t want future patients to hope for survival months; I want them to hope for decades. 

Her rare cancer, affecting less than 0.3% of thyroid malignancies worldwide, revealed the limits of current medicine—and the responsibility of those willing to seek answers. She shifted my view of science from classroom learning to real-world experience lived in hospitals, chronicled in discharge summaries, felt in moments of silence. 

That’s why I chose research. Because between the hospital bed and the pathology report, I stopped just treating disease; I started seeking to understand it. Studying genes, pathways, microenvironments that influence why some cells heal, and others mutate to harm. 

Her life didn’t end with her illness without breakthroughs, yet she gave me a reason to pursue them. Her strength became my bridge from grief to purpose. She showed me science isn’t cold; it’s compassionate inquiry, a courage to face suffering and ask, "What can we do better next time?"

This is what I dedicate my career to: advancing cancer biology so stories like hers don’t end in uncertainty but in hope.